Development of quality of care indicators for Parkinson's disease

Cheng, Eric M.; Siderowf, Andrew; Swarztrauber, Kari; Eisa, Mahmood; Lee, Martin; Vickrey, Barbara G.

doi:10.1002/mds.10664

Cited by 34 publications

(42 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 In their analysis, a comprehensive set of 79 potential quality indicators for PD care were first identified based on an extensive review of the medical literature. An expert panel of 7 movement disorder specialists then rated each indicator for several different criteria: validity, feasibility, impact on outcomes, overall utility, and room for improvement.…”

Section: Quality Of Care For Pdmentioning

confidence: 99%

“…8 One indicator with high potential to improve the quality of care is to evaluate if the initial or subsequent treatment is wearing off and to manage any problems appropriately (Table 1). Entacapone, rasagiline, or a dopamine agonist can be used as adjunctive therapy with levodopa for management of motor fluctuations.…”

Section: Quality Indicators For Management Of Motor Complicationsmentioning

confidence: 99%

“…With respect to COMT inhibitors, entacapone should be used before tolcapone, and if tolcapone is given for adjunctive therapy, liver function testing should occur regularly as per the new labeling recommendations. 8 Effective management of dyskinesias can also improve the quality of patient care.…”

Section: Quality Indicators For Management Of Motor Complicationsmentioning

confidence: 99%

“…One PD-specific quality indicator with high potential for quality improvement is the appropriate management of orthostatic hypotension. 8 Clinicians and providers should also consider treatment for constipation, urological symptoms, swallowing difficulties, and speech dysfunction to improve the quality of life for PD patients.…”

Section: Quality Indicators and Summary For Management Of Nonmotor Comentioning

confidence: 99%

“…Based on an expert consensus process, the indicators with the highest potential to improve the management of PD include conducting a proper assessment for depression, using quetiapine or clozapine to treat persistent hallucinations, and the possibility of withdrawal or reduction of medications that can cause hallucinations. 8 It is highly recommended to monitor white blood cell counts (WBCs) in patients receiving clozapine to check for agranulocytosis. 8 Additionally, an assessment of the decision-making capacity should be done for PD patients with dementia.…”

Section: Quality Indicators For the Management Of Dementia Depressiomentioning

confidence: 99%

See 4 more Smart Citations

Treatment Strategies and Quality-of-Care Indicators for Patients With Parkinson's Disease

Chen¹,

Lew²,

Siderowf³

2009

JMCP

Self Cite

View full text Add to dashboard Cite

Droxidopa has orphan status for the treatment of orthostatic hypotension and is currently not approved for this use in the United States. Currently, donepezil is not FDA approved for treatment of dementia in patients with Parkinson's disease. While fludrocortisone has been used to treat orthostatic hypotension, it does not have FDA approval. Selegiline does have FDA approval for use as an adjunct to levodopa treatment; however, it is not approved for monotherapy to treat Parkinson's disease. Additionally, tamsulosin and terazosin are approved for the treatment of benign prostatic hyperplasia but have been used to treat urinary dysfunction, which is a symptom of prostatic hyperplasia. AcknowledgementsThe authors acknowledge Chris R. Prostko, PhD, and Joanne M. Faysal, BS, from PRIME ® (Tamarac, Florida) for their assistance with the development and revision of this supplement. Alexandria, VA 22314; 703.683.8416; 703.683.8417 (fax F a c u l t y Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. 6. Seek and publish content that does not duplicate content in the Journal of Managed Care Pharmacy. 7. Subject all supplements to expert peer review. Target AudienceThe target audience for this activity is managed care pharmacists and managed care physicians. This is an applicationbased learning activity. Learning ObjectivesUpon completion of this program, participants will be able to: Funding and Original Presentation of This Learning ActivityThis supplement was sponsored by PRIME ® through an independent educational grant from Teva Neuroscience. This supplement is based on the proceedings of a satellite symposium held October 15, 2008, at the Kansas City Convention Center in Kansas City, Missouri, in conjunction with the Academy of Managed Care Pharmacy's 2008 Educational Conference, which was supported by an independent grant from Teva Neuroscience. Epidemiology and Pathophysiology of PDParkinson's disease (PD) presently affects over 1 million people in the United States. While PD can occ...

show abstract

Section: Quality Of Care For Pdmentioning

confidence: 99%

Section: Quality Indicators For Management Of Motor Complicationsmentioning

confidence: 99%

Section: Quality Indicators For Management Of Motor Complicationsmentioning

confidence: 99%

Section: Quality Indicators and Summary For Management Of Nonmotor Comentioning

confidence: 99%

Section: Quality Indicators For the Management Of Dementia Depressiomentioning

confidence: 99%

See 3 more Smart Citations

Treatment Strategies and Quality-of-Care Indicators for Patients With Parkinson's Disease

Chen¹,

Lew²,

Siderowf³

2009

JMCP

Self Cite

View full text Add to dashboard Cite

show abstract

Depression in veterans with Parkinson's disease: frequency, co‐morbidity, and healthcare utilization

Chen

Kales

Weintraub

et al. 2006

Int J Geriat Psychiatry

View full text Add to dashboard Cite

Depression in PD in non-tertiary care settings may not be as common or as severe as that seen in specialty care, though these findings also may reflect under-recognition or diagnostic imprecision. The occurrence of depression in PD is associated with greater psychiatric and medical co-morbidity, and greater healthcare utilization. These findings suggest that screening for depression in PD is important and should be embedded in a comprehensive psychiatric, neuropsychological, and medical evaluation.

show abstract

Association of specialist involvement and quality of care for Parkinson's disease

et al. 2007

Self Cite

View full text Add to dashboard Cite

Because Parkinson's disease (PD) has multiple neurological symptoms and often complex treatments, the quality of PD care may be higher when a specialist is involved. We examined the medical records, from 1998 to 2004, of 401 Los Angeles veterans with Parkinson's disease to determine whether care met key indicators of PD care quality. All care following a visit to a movement-disorder specialist or general neurologist was classified as specialty care. We compared adherence to each indicator by level of specialist involvement through logistic regression models. Over the study period, 10 indicators of PD care quality were triggered 2,227 times. Overall, movement disorder specialist involvement (78%) was associated with higher adherence to indicators than did general neurologist involvement (70%, P = 0.006) and nonneurologist involvement (52%, P < 0.001). The differences between movement disorder specialist and nonneurologist involvement were especially large for four indicators: treatment of wearing-off, assessments of falls, depression, and hallucinations. There is significant room for improving aspects of PD care quality among patients who do not have the involvement of a specialist. Quality of care interventions should involve specialists in management of motor symptoms and incorporate methods for routine assessment of nonmotor PD symptoms.

show abstract

Development of quality of care indicators for Parkinson's disease

Cited by 34 publications

References 43 publications

Treatment Strategies and Quality-of-Care Indicators for Patients With Parkinson's Disease

Treatment Strategies and Quality-of-Care Indicators for Patients With Parkinson's Disease

Depression in veterans with Parkinson's disease: frequency, co‐morbidity, and healthcare utilization

Association of specialist involvement and quality of care for Parkinson's disease

Contact Info

Product

Resources

About